ClinicalTrials.gg
DrugBiological

Nirsevimab clinical trials

Also written MEDI8897 and Beyfortus.

studies test it
15
open now
3
in phase 3
6
first study started
2014

How each study uses nirsevimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the nirsevimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Jul 2023 · BEYFORTUS · BLA 761328 (FDA, Drugs@FDA)
European Union
31 Oct 2022 · Beyfortus · EMEA/H/C/005304 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nirsevimab
8

Brand

Beyfortus
3

Development codes

MEDI8897
6

Studies by the year they started

15 studies that test it; most in 2025 (3)

Studies that test nirsevimab, by start year
YearStudies
20141
20151
20161
20192
20201
20212
20221
20231
20241
20253
20261

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
3
Phase 3
6
Phase 4
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 11 · Other 4

AstraZeneca (6) · MedImmune LLC (3) · Sanofi (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Sanofi Pasteur, a Sanofi Company (1) · PENTA Foundation (1) · Menzies School of Health Research (1) · Duke University (1)

Often tested with

Tested in the same studies.

Abrysvo (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test nirsevimab.

Studies

Open first, then newest update. How each study uses nirsevimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 15

Given beside what is tested · 1 — nirsevimab is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with nirsevimab

Codes

What other systems call nirsevimab · ClinicalTrials.gg INT001398

  • MeSH (NLM) C000709769nirsevimabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) VRN8S9CW5VNIRSEVIMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q111535760nirsevimabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C170224NirsevimabOne source FDA
  • DrugBank DB16258One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.